Cargando…
Correction: Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7371019/ https://www.ncbi.nlm.nih.gov/pubmed/32690666 http://dx.doi.org/10.1136/jitc-2019-000437corr1 |
| _version_ | 1783561069975830528 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7371019 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | BMJ Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-73710192020-07-22 Correction: Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study J Immunother Cancer Correction BMJ Publishing Group 2020-07-19 /pmc/articles/PMC7371019/ /pubmed/32690666 http://dx.doi.org/10.1136/jitc-2019-000437corr1 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
| spellingShingle | Correction Correction: Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study |
| title | Correction: Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study |
| title_full | Correction: Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study |
| title_fullStr | Correction: Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study |
| title_full_unstemmed | Correction: Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study |
| title_short | Correction: Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study |
| title_sort | correction: tislelizumab in chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7371019/ https://www.ncbi.nlm.nih.gov/pubmed/32690666 http://dx.doi.org/10.1136/jitc-2019-000437corr1 |